Global Postherpetic Neuralgia Market Overview
Postherpetic neuralgia (PHN) is a type of neuropathic pain that is caused by an injury. In many situations, the recurrence of the varicella zoster virus causes harm to the peripheral nerves. Herpes zoster, also known as shingles, is caused by the virus. Neuralgia is more common in places with only one sensory nerve. The pain from post-herpetic neuralgia can continue up to 85 days. In addition to PHN, a person may have a variety of additional health problems. Itching, strange sensations, pain from gentle contact, hyperalgesia, and so on. Intermittent or continuous nerve pain in a previously shingles-affected location is the most common sign of post-herpetic neuralgia. The discomfort may come and go or be constant. Burning, stabbing, shooting, hurting, throbbing, or electric shocks are among descriptions that come to mind. In addition, the impacted area may be more sensitive to pain than usual experience pain as a result of something that should not hurt, such as a gentle touch or a cool breeze. Postherpetic neuralgia (PHN) is a type of nerve pain produced by the reactivation of the varicella zoster virus, which causes damage to a peripheral nerve (shingles). PHN is nerve pain that lasts longer than 30 days after herpes zoster reactivation. Damage to the peripheral nerve is the cause of the nerve pain.Postherpetic Neuralgia Market was valued at US$ 803 million in 2024 and is projected to grow at a CAGR of 5.6% to reach US$ 1320.9 million by 2034.
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Global Postherpetic Neuralgia Market Drivers & Restraints
- New drug development
The postherpetic neuralgia therapy industry has a huge market opportunity for new medication development. Due to the absence of rivalry in the post herpetic neuralgia treatment market, the development of any curative post herpetic neuralgia treatment medicine is projected to promote a faster market acceptance with less resources. Because there is no cure for postherpetic neuralgia, the main purpose of treatment is to alleviate symptoms.
- Government support enhance the market
Other factors likely to enhance the growth of the after herpetic neuralgia treatment market include government support for post herpetic neuralgia treatment products and efforts in various countries. The ageing of the global population and rising healthcare spending are two demographic drivers of the post herpetic neuralgia therapy market.
Recent Development:
- In July 2022, Acasti Pharma, Inc. declared that the pharmacokinetic study for GTX-101, the company's drug candidate for postherpetic neuralgia therapy, has begun. GTX-101 is a novel formulation of bupivacaine hydrochloride (HCl) for topical administration via a bio-adhesive, film-forming polymer, in order to alleviate the pain associated with Postherpetic Neuralgia (PHN), a persistent and frequently crippling neuropathic pain brought on by nerve damage from the varicella zoster virus (shingles), which can last for months or even years, GTX-101 is a novel formulation of bupivacaine hydrochloride (HCl) for topical administration via a bio-adhesive, film-forming polymer.
Global Postherpetic Neuralgia Market Segmentations & Regional Insights
Disclaimer: Data is only a representation. Actual data may vary in the final report.
The post herpetic neuralgia treatment market can be segmented based on type, distribution channel, and region.
On the basis of Type, the Postherpetic Neuralgia Market is segmented into Patches, Drugs, and Opioids. Based on Distribution Channel, the target market is segmented into hospital pharmacies, drug stores, retail pharmacies, and others.
Regional Insights:
On region the Postherpetic Neuralgia Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In the future years, North America is likely to dominate the market. This is attributable to the population's stronger purchasing power, a developed economy, better reimbursement rules, an increase in the incidence of postherpetic neuralgia, the presence of significant players, and increased health-care spending. For example, health-care spending in the United States accounted for roughly 16% of GDP in 2017. The market is likely to be dominated by Europe and Asia Pacific. The market in Asia Pacific is predicted to grow due to factors such as an ageing population and large investments in health care infrastructure. The presence of quickly rising economies in the region, such as India, China, and the Philippines, is projected to increase the postherpetic neuralgia treatment market.
Postherpetic Neuralgia Market, By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Global Postherpetic Neuralgia Market Competitive Landscape & Key Players
Some of the key players operating in the global post herpetic neuralgia treatment market are Pfizer Inc, Teikoku Pharma USA, Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Endo Pharmaceuticals Inc.. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market.
Global Postherpetic Neuralgia Market Company Profile
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Teikoku Pharma USA, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Janssen Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Teva Pharmaceuticals Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Endo Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
Global Postherpetic Neuralgia Market Highlights
FAQs
The Global Postherpetic Neuralgia Market is segmented based on type, distribution channel, and Region.
New drug development which is the major factor driving growth of the global market
North America is likely to dominate the market. This is attributable to the population's stronger purchasing power, a developed economy, better reimbursement rules, an increase in the incidence of postherpetic neuralgia, the presence of significant players, and increased health-care spending.
Some of the key players operating in the global post herpetic neuralgia treatment market are Pfizer Inc, Teikoku Pharma USA, Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Endo Pharmaceuticals Inc.